A Phase 1b/2, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of TJ003234 in Subjects with Severe Coronavirus Disease 2019 (COVID-19)

C
Chadi Hage, MD

Primary Investigator

Overview

The purpose of this study is to evaluate the safety and efficacy of TJ003234 in subjects with severe COVID-19 with supportive care.

Description

Participants will be randomly assigned to receive either a single dose of 3 mg/kg TJ003234, a single dose of 6 mg/kg TJ00324, or placebo, administered by IV infusion. Participants will be monitored for 30 days following their last dose.

Eligibility

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    COVID-19
  • Age: Between 18 Years - 100 Years
  • Gender: All

Individuals at least 18 years of age with laboratory confirmed diagnosis of COVID-19, with severe disease.

Individuals with certain comorbidities will not be eligible.

Women who are pregnant or breastfeeding will not be eligible.

Updated on 20 Nov 2022. Study ID: 2003014335

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center